Talk:Lamotrigine: Difference between revisions
Content deleted Content added
content from to-do, make sections, sign unsigned |
m Archiving 1 discussion(s) to Talk:Lamotrigine/Archive 2) (bot |
||
| (23 intermediate revisions by 12 users not shown) | |||
| Line 1: | Line 1: | ||
{{Reliable sources for medical articles}} |
{{Reliable sources for medical articles}} |
||
{{talk header}} |
|||
| ⚫ | |||
{{WikiProject |
{{WikiProject banner shell|class=B| |
||
{{WikiProject Medicine |importance=mid}} |
|||
| ⚫ | |||
{{notaforum|getting medical advice, reporting your symptoms and reactions to the drug, and so on.}} |
|||
}} |
|||
{{Archive box|auto=long}} |
|||
{{User:MiszaBot/config |
{{User:MiszaBot/config |
||
|archiveheader = {{atnhead|noredlinks=y}} |
|archiveheader = {{atnhead|noredlinks=y}} |
||
|maxarchivesize = 40K |
|maxarchivesize = 40K |
||
|counter = |
|counter = 2 |
||
|minthreadsleft = |
|minthreadsleft = 2 |
||
|minthreadstoarchive = 0 |
|minthreadstoarchive = 0 |
||
|algo = old( |
|algo = old(180d) |
||
|archive = Talk:Lamotrigine/Archive %(counter)d |
|archive = Talk:Lamotrigine/Archive %(counter)d |
||
}} |
}} |
||
{{Auto archiving notice |bot=MiszaBot I |age=28 |small=yes |dounreplied=yes}} |
|||
==Side effects== |
|||
According to Bertram G. Katzung's 7th Edition of basic and clinical pharmacology on page 396, Lamotrigine's symptoms can include dizziness, somnolence, headache, diplopia, nausea, and rash. Sometimes the rash can be a mild and itchy adverse reaction in the skin (personal experience), since it has been said to bind to melanin there and in the eyes (I don't remember where I heard this, but it was a legitimate source). Lamotrigine has a serious risk in its potential for steven's johnson's syndrome, which begins manifestation as a rash. This is why it is essential that lamotrigine treatment begin slowly--the book mentioned above states that patients taking valproate must begin treatment at no more than 25mg every other day. Steven's Johnson's syndrome is rare, and it is almost unheard of after a patient has finished transitioning onto the medication. |
|||
As with any medication, it's a strain on the body, common sense indicates that users need more water while taking this medication. I think it made me sweat more as well, which might be attributable to its moderately high level of protein binding (the book says 55%). I am not an M.D., but an economics student and informed patient. good luck! (1st contribution to wikipedia, sorry if this is a poor one!) <!-- Template:Unsigned --><small class="autosigned">— Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[User:167.206.48.221|167.206.48.221]] ([[User talk:167.206.48.221#top|talk]] • [[Special:Contributions/167.206.48.221|contribs]]) 22:57, 15 February 2012 (UTC)</small> |
|||
== Sleep disturb % is misstated. == |
|||
Not, "However, a retrospective study of 109 patients' medical records found that 6.7% of patients experienced an "alerting effect" resulting in intolerable insomnia, for which the treatment had to be discontinued. (65)" |
|||
==Legal status in Japan== |
|||
I'm not sure if I'm putting this in the correct section. However, here goes: as a user of Lamictal and frequent visitor to Japan I was concerned to read about lamotrigine's classification as a narcotic in Japan. Japan has some worryingly bureaucratic processes around the importation of medicines. After conversation with the local Japanese consulate, and some detailed web searching, I faxed some questions about lamotrigine to the relevant department in Japan. This is the reply I got: |
|||
Dear Mr. [name removed] |
|||
I got fax from you. |
|||
Lamictal is NOT a narcotic drug (it is a prescription drug) in Japan, so you do not need to fill in an application form to import a narcotic. |
|||
Under the Japanese regulation of importing drugs, people can import one month supply of prescription drugs without any procedures. If the quantity of Lamictal you intend to bring into Japan is less than one month supply, you do not need to fill in any forms. A prescription from your doctor would make customs clearance smooth. |
|||
If you intend to bring more than one month supply, you need to fill in “Import Report for Medication” form and apply for the Yakkan Shoumei, a kind of import certification. You have to apply for the Yakkan Shoumei” every time you visit Japan if you bring more than one month supply each time. |
|||
Regarding the Yakkan Shoumei, please check our website below: |
|||
http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/01.html |
|||
Regards. |
|||
[name removed] |
|||
Section Chief |
|||
Section for Import Monitoring of Medical Products |
|||
Compliance and Narcotics Division |
|||
Pharmaceutical and Food Safety Bureau |
|||
Ministry of Health, Labour and Welfare, JAPAN |
|||
It's only 6.4%. |
|||
Accordingly, unless someone has other information, I believe the section about the legal status of this drug needs to be changed. MMCW83 [[User:MMCW83|MMCW83]] ([[User talk:MMCW83|talk]]) 08:14, 12 July 2012 (UTC) |
|||
65) Sadler M (March 1999). "Lamotrigine associated with insomnia". Epilepsia. 40 (3): 322–5. doi:10.1111/j.1528-1157.1999.tb00712.x. PMID 10080513. S2CID 43902298. [[Special:Contributions/98.144.238.191|98.144.238.191]] ([[User talk:98.144.238.191|talk]]) 17:28, 29 June 2022 (UTC) |
|||
==Half-life== |
|||
Fix inconsistency re: half-life information. In the Pharmacokinetic data table it is listed as 29 hours and in the body (Pharmacokinetics) it is listed as 13.5 hours <!-- Template:Unsigned --><small class="autosigned">— Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[User:97.123.50.242 |97.123.50.242 ]] ([[User talk:97.123.50.242 #top|talk]] • [[Special:Contributions/97.123.50.242 |contribs]]) 15:51, 22 October 2014 (UTC)</small> |
|||
How to take this medication. Empty stomach? With food? Time of day? Etc. [[Special:Contributions/68.66.100.253|68.66.100.253]] ([[User talk:68.66.100.253|talk]]) 14:36, 8 January 2024 (UTC) |
|||
== Receptor activity listed in article not found in cited source == |
|||
== Bad Pharma == |
|||
Receptor activity is listed as antagonistic at 5-HT3 and σ receptors with IC50 of 18 μM and 145 μM, respectively. The inline citation is [5] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678. Neither the live webpage cited nor the archived version make any mention of antagonistic activity at 5-HT3 or σ receptors unless I'm mistaken. Moreover, the ligands section of the [[sigma receptor]] page lists Lamotrigine as an *agonist* of the σ receptors with two inline citations, one of which I can't access and the other of which makes no mention of activity at σ receptors at all. [[User:UriNation69420|UriNation69420]] ([[User talk:UriNation69420|talk]]) 17:21, 26 June 2024 (UTC) |
|||
The book Bad Pharma notes that 63% of the trials of this drug have not been published. When dealing with medications, should we consult www.alltrials.net ? People do rely on the information provided by Wiki and if we are passing on bad data, people may be harmed. I know that this would be a huge amount of work but I am prepared to cover as many as possible. I've added patents & papers to over 800 pages (from several IP addresses, but you can spot my standard 'added patent' format. |
|||
If Wiki supports alltrials, we will be providing information for both doctors and patients. To do this properly we need to get alltrials and specifically Dr. Ben Goldacre to find a feedback mechanism. In addition, checking references with retraction watch will ensure that we give only the best, unbiased references to users. I feel strongly about this because Lamotragine almost killed me because of an unreported side-effect. Maybe the side-effect WOULD be known if the trials were ALL published. <!-- Template:Unsigned IP --><small class="autosigned">— Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[Special:Contributions/81.99.74.135|81.99.74.135]] ([[User talk:81.99.74.135#top|talk]]) 22:28, 1 January 2017 (UTC)</small> <!--Autosigned by SineBot--> |
|||
:Patents are not reliable sources in WP, so you have added a bunch of bad referencing that is probably [[WP:OR]] to boot - you need some secondary source that says patent X is relevant to drug Y. See [[WP:SPS]] which specifically mentions patents. I hope you will undo all those edits. |
|||
:about alltrials... raw clinical trial data is also not useful in WP; we rely on secondary sources for health content per [[WP:MEDRS]]. [[User:Jytdog|Jytdog]] ([[User talk:Jytdog|talk]]) 06:55, 2 January 2017 (UTC) |
|||
Latest revision as of 14:11, 27 June 2024
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lamotrigine.
|
| This is the talk page for discussing improvements to the Lamotrigine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1, 2Auto-archiving period: 6 months  |
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
Sleep disturb % is misstated.
[edit]Not, "However, a retrospective study of 109 patients' medical records found that 6.7% of patients experienced an "alerting effect" resulting in intolerable insomnia, for which the treatment had to be discontinued. (65)"
It's only 6.4%.
65) Sadler M (March 1999). "Lamotrigine associated with insomnia". Epilepsia. 40 (3): 322–5. doi:10.1111/j.1528-1157.1999.tb00712.x. PMID 10080513. S2CID 43902298. 98.144.238.191 (talk) 17:28, 29 June 2022 (UTC)
How to take this medication. Empty stomach? With food? Time of day? Etc. 68.66.100.253 (talk) 14:36, 8 January 2024 (UTC)
Receptor activity listed in article not found in cited source
[edit]Receptor activity is listed as antagonistic at 5-HT3 and σ receptors with IC50 of 18 μM and 145 μM, respectively. The inline citation is [5] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678. Neither the live webpage cited nor the archived version make any mention of antagonistic activity at 5-HT3 or σ receptors unless I'm mistaken. Moreover, the ligands section of the sigma receptor page lists Lamotrigine as an *agonist* of the σ receptors with two inline citations, one of which I can't access and the other of which makes no mention of activity at σ receptors at all. UriNation69420 (talk) 17:21, 26 June 2024 (UTC)